S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
'The Sacrifice Zone': Myanmar bears cost of green energy
Can Etsy Continue to Thrive After the Pandemic?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
'The Sacrifice Zone': Myanmar bears cost of green energy
Can Etsy Continue to Thrive After the Pandemic?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
'The Sacrifice Zone': Myanmar bears cost of green energy
Can Etsy Continue to Thrive After the Pandemic?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
'The Sacrifice Zone': Myanmar bears cost of green energy
Can Etsy Continue to Thrive After the Pandemic?
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
NASDAQ:HARP

Harpoon Therapeutics - HARP Stock Forecast, Price & News

$2.16
+0.03 (+1.41%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.12
$2.23
50-Day Range
$1.86
$2.56
52-Week Range
$1.73
$10.60
Volume
145,036 shs
Average Volume
119,393 shs
Market Capitalization
$71.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.89

Harpoon Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
496.7% Upside
$12.89 Price Target
Short Interest
Healthy
3.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.56
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.17) to ($2.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

265th out of 1,098 stocks

Biological Products, Except Diagnostic Industry

40th out of 174 stocks

HARP stock logo

About Harpoon Therapeutics (NASDAQ:HARP) Stock

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Harpoon Therapeutics Stock Performance

NASDAQ:HARP opened at $2.16 on Tuesday. Harpoon Therapeutics has a 1 year low of $1.73 and a 1 year high of $10.60. The company has a fifty day moving average of $2.19 and a two-hundred day moving average of $3.32.

Harpoon Therapeutics (NASDAQ:HARP - Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.14). Harpoon Therapeutics had a negative net margin of 366.46% and a negative return on equity of 112.69%. The company had revenue of $5.91 million during the quarter, compared to analyst estimates of $11.31 million. As a group, analysts predict that Harpoon Therapeutics will post -2.17 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on HARP shares. Piper Sandler lowered their price objective on shares of Harpoon Therapeutics from $14.00 to $9.00 in a report on Friday, May 27th. Wedbush increased their target price on Harpoon Therapeutics from $5.00 to $7.00 and gave the stock an "outperform" rating in a report on Monday, May 16th. Roth Capital raised their target price on Harpoon Therapeutics from $14.00 to $18.00 in a research report on Tuesday, May 17th. Cantor Fitzgerald restated an "overweight" rating on shares of Harpoon Therapeutics in a research note on Monday, May 9th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $16.00 price objective on shares of Harpoon Therapeutics in a report on Wednesday, July 6th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $12.89.

Receive HARP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HARP Stock News Headlines

Harpoon Therapeutics (NASDAQ:HARP) Shares Up 1.4%
Harpoon Therapeutics Expands Leadership Team
Analyst Ratings for Harpoon Therapeutics
Harpoon Therapeutics falls as medical chief exits
Harpoon Therapeutics Announces Leadership Change
Corporate update from portfolio company Harpoon Therapeutics
See More Headlines
Receive HARP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HARP Company Calendar

Last Earnings
5/12/2022
Today
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HARP
Fax
N/A
Employees
99
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.89
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+496.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-116,720,000.00
Net Margins
-366.46%
Pretax Margin
-366.46%

Debt

Sales & Book Value

Annual Sales
$23.65 million
Book Value
$1.77 per share

Miscellaneous

Free Float
28,783,000
Market Cap
$71.45 million
Optionable
Not Optionable
Beta
1.41














HARP Stock - Frequently Asked Questions

Should I buy or sell Harpoon Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HARP shares.
View HARP analyst ratings
or view top-rated stocks.

What is Harpoon Therapeutics' stock price forecast for 2022?

8 equities research analysts have issued 1 year price objectives for Harpoon Therapeutics' stock. Their HARP share price forecasts range from $7.00 to $18.00. On average, they expect the company's share price to reach $12.89 in the next twelve months. This suggests a possible upside of 496.7% from the stock's current price.
View analysts price targets for HARP
or view top-rated stocks among Wall Street analysts.

How has Harpoon Therapeutics' stock performed in 2022?

Harpoon Therapeutics' stock was trading at $7.55 on January 1st, 2022. Since then, HARP stock has decreased by 71.4% and is now trading at $2.16.
View the best growth stocks for 2022 here
.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) released its quarterly earnings results on Thursday, May, 12th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.14. The business earned $5.91 million during the quarter, compared to analyst estimates of $11.31 million. Harpoon Therapeutics had a negative net margin of 366.46% and a negative trailing twelve-month return on equity of 112.69%.

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

4 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

How do I buy shares of Harpoon Therapeutics?

Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $2.16.

How much money does Harpoon Therapeutics make?

Harpoon Therapeutics (NASDAQ:HARP) has a market capitalization of $71.46 million and generates $23.65 million in revenue each year. The company earns $-116,720,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis.

How many employees does Harpoon Therapeutics have?

Harpoon Therapeutics employs 99 workers across the globe.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.harpoontx.com. The company can be reached via phone at (650) 443-7400 or via email at ir@harpoontx.com.

This page (NASDAQ:HARP) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.